Genocea Announces Upcoming Data Presentations at Virtual SITC 2020
Will showcase clinical and immune responses from the ongoing GEN-009 Phase 1/2a trial
Will provide a detailed introduction to GEN-011, an adoptive T cell therapy designed to improve upon the limitations of TIL and TCR therapies
Will share new insights on the utility of InhibigensTM as identified by ATLASTM to inform immunotherapy development
CAMBRIDGE, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced the titles and times of its presentations at the upcoming 35th Annual Meeting of The Society for Immunotherapy of Cancer (SITC 2020) taking place virtually November 9th – 14th.
The following posters will be available on Monday, November 9 at 8 a.m. ET:
Abstract Nuber: 390
Abstract Number: 413
Abstract Number: 149
Abstract Number: 526
Per SITC policy, full abstracts are embargoed until 8 a.m. ET on November 9, 2020.
About Genocea Biosciences, Inc.